Two Sigma Advisers LP acquired a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 606,700 shares of the company's stock, valued at approximately $1,432,000. Two Sigma Advisers LP owned about 1.26% of Cassava Sciences as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of SAVA. Deutsche Bank AG boosted its stake in shares of Cassava Sciences by 42.7% during the fourth quarter. Deutsche Bank AG now owns 36,571 shares of the company's stock worth $86,000 after buying an additional 10,940 shares during the period. Apollon Wealth Management LLC acquired a new stake in Cassava Sciences during the 4th quarter worth approximately $73,000. Raymond James Financial Inc. purchased a new position in shares of Cassava Sciences in the 4th quarter valued at approximately $147,000. Marshall Wace LLP acquired a new position in shares of Cassava Sciences in the fourth quarter valued at approximately $50,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Cassava Sciences by 5,905.4% during the fourth quarter. Russell Investments Group Ltd. now owns 22,220 shares of the company's stock worth $52,000 after purchasing an additional 21,850 shares during the last quarter. 38.05% of the stock is owned by hedge funds and other institutional investors.
Cassava Sciences Trading Down 0.5%
Shares of Cassava Sciences stock traded down $0.01 on Wednesday, reaching $2.15. 674,785 shares of the stock were exchanged, compared to its average volume of 3,014,886. The firm has a market capitalization of $103.86 million, a PE ratio of -1.56 and a beta of -2.00. Cassava Sciences, Inc. has a 1-year low of $1.15 and a 1-year high of $42.20. The business has a fifty day moving average price of $1.67 and a two-hundred day moving average price of $3.20.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. Research analysts expect that Cassava Sciences, Inc. will post -3.97 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "neutral" rating and issued a $2.00 price objective on shares of Cassava Sciences in a research report on Tuesday, March 25th.
Get Our Latest Report on SAVA
Cassava Sciences Profile
(
Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
